Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today
Sign in to our library of over $5 million worth of researchclose

Two Quick Steps

* Required Fields

Click Your Industry



Registered Customers

If you have an account with us, please log in.

* Required Fields



Subscribe today

We deliver Mobile Wallet Market Research and SWOT Analysis from Alternative Energy to Pharmaceuticals and Healthcare Market Research Reports to Digital Media.

Skip to Main Content »

Search Site
Researchers Currently Online:1397

Cell Therapeutics, Inc. (CTIC) - Financial and Strategic SWOT Analysis Review

Cell Therapeutics, Inc. (CTIC) - Financial and Strategic SWOT Analysis Review

Double click on above image to view full picture

Zoom Out
Zoom In
Additional Information
Price $125.00
Meta Description Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company. It develops and commercializes integrated portfolio of oncology products. The company's product pipeline include Pixuvri (pixantrone dimaleate), is under development for the treatment of non-Ho
Publisher GlobalData
Date of Report Dec 3, 2013
Quick Overview
Summary

Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company. It develops and commercializes integrated portfolio of oncology products. The company's product pipeline include Pixuvri (pixantrone dimaleate), is under development for the treatment of non-Hodgkin lymphoma (NHL); Tosedostat, is in Phase II clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplasia (MDS); Brostallicin, being studied for the treatment of triple-negative metastatic breast cancer in Phase II and III; Novel Bisplatinum Analogues; Opaxio (paclitaxel poliglumex), for the treatment of solid tumors and Pacritinib, is in Phase II clinical trial for the treatment of myelofibrosis.

Cell Therapeutics, Inc. Key Recent Developments

Feb 28, 2013: Cell Therapeutics Reports 2012 Results
Nov 01, 2012: Cell Therapeutics Reports Q3 2012 Results
Sep 19, 2012: Cell Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Rule
Aug 01, 2012: Cell Therapeutics Reports Q2 2012 Results
Jun 14, 2012: Cell Therapeutics Appoints Steven Benner As Chief Medical OfficerGDPH34546FSA

This comprehensive SWOT profile of Cell Therapeutics, Inc. provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Key manufacturing facilities – A list of key manufacturing facilities of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Table of Contents
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Section 1 - About the Company 5
Cell Therapeutics, Inc. - Key Facts 5
Cell Therapeutics, Inc. - Key Employees 6
Cell Therapeutics, Inc. - Key Employee Biographies 7
Cell Therapeutics, Inc. - Major Products and Services 9
Cell Therapeutics, Inc. - Pharmaceutical Pipeline Products Data 10
Cell Therapeutics, Inc., Pipeline Products by Therapy Area 10
Cell Therapeutics, Inc., Pipeline Products by Development Phase 11
Cell Therapeutics, Inc. - History 14
Cell Therapeutics, Inc. - Company Statement 16
Cell Therapeutics, Inc. - Locations And Subsidiaries 18
Head Office 18
Other Locations & Subsidiaries 18
Section 2 – Company Analysis 19
Cell Therapeutics, Inc. - Business Description 19
Cell Therapeutics, Inc. - Corporate Strategy 20
Cell Therapeutics, Inc. - SWOT Analysis 21
SWOT Analysis - Overview 21
Cell Therapeutics, Inc. - Strengths 21
Strength - Collaborative Agreements 21
Strength - Strong Technological Base 21
Cell Therapeutics, Inc. - Weaknesses 21
Weakness - Lack of Manufacturing Facilities 21
Weakness - Sale of Zevalin 21
Weakness - Legal Proceedings 22
Cell Therapeutics, Inc. - Opportunities 22
Opportunity - Market Potential: Cancer 22
Opportunity - Strong Base of Pipeline Products 22
Opportunity - Changing Demographics 23
Cell Therapeutics, Inc. - Threats 23
Threat - Uncertain R&D Outcomes 23
Threat - Intense Competition 23
Threat - Stringent Government Regulations 23
Cell Therapeutics, Inc. - Key Competitors 24
Section 3 – Company Financial Ratios 25
Financial Ratios - Capital Market Ratios 25
Financial Ratios - Annual Ratios 25
Performance Chart 27
Financial Performance 27
Financial Ratios - Interim Ratios 28
Financial Ratios - Ratio Charts 29
Section 4 – Company’s Lifesciences Financial Deals and Alliances 30
Cell Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 30
Cell Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 31
Cell Therapeutics, Inc., Recent Deals Summary 32
Section 5 – Company’s Recent Developments 33
Cell Therapeutics, Inc., Recent Developments 33
Feb 28, 2013: Cell Therapeutics Reports 2012 Results 33
Nov 01, 2012: Cell Therapeutics Reports Q3 2012 Results 34
Sep 19, 2012: Cell Therapeutics Regains Compliance With NASDAQ Minimum Bid Price Rule 35
Aug 01, 2012: Cell Therapeutics Reports Q2 2012 Results 35
Jun 14, 2012: Cell Therapeutics Appoints Steven Benner As Chief Medical Officer 36
Apr 20, 2012: Cell Therapeutics Reports Q1 2012 Results 36
Mar 07, 2012: Cell Therapeutics Reports Q4 2011 Results 36
Section 6 – Appendix 38
Methodology 38
Ratio Definitions 38
About GlobalData 42
Contact Us 42
Disclaimer 42

List of Tables
Cell Therapeutics, Inc., Key Facts 5
Cell Therapeutics, Inc., Key Employees 6
Cell Therapeutics, Inc., Key Employee Biographies 7
Cell Therapeutics, Inc., Major Products and Services 9
Cell Therapeutics, Inc., Number of Pipeline Products by Therapy Area 10
Cell Therapeutics, Inc., Number of Pipeline Products by Development Stage 11
Cell Therapeutics, Inc., Pipeline Products By Therapy Area and Development Phase 12
Cell Therapeutics, Inc., History 14
Cell Therapeutics, Inc., Subsidiaries 18
Cell Therapeutics, Inc., Key Competitors 24
Cell Therapeutics, Inc., Ratios based on current share price 25
Cell Therapeutics, Inc., Annual Ratios 25
Cell Therapeutics, Inc., Interim Ratios 28
Cell Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 30
Cell Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Type, 2007 to YTD 2013 31
Cell Therapeutics, Inc., Recent Deals Summary 32
Currency Codes 38
Capital Market Ratios 38
Equity Ratios 39
Profitability Ratios 39
Cost Ratios 40
Liquidity Ratios 40
Leverage Ratios 41
Efficiency Ratios 41

List of Figures
Cell Therapeutics, Inc., Pipeline Products by Therapy Area 10
Cell Therapeutics, Inc., Pipeline Products by Development Phase 11
Cell Therapeutics, Inc., Performance Chart (2007 - 2011) 27
Cell Therapeutics, Inc., Ratio Charts 29
Cell Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals By Year, 2007 to YTD 2013 30
Cell Therapeutics, Inc., Pharmaceuticals & Healthcare, Deals by Type, 2007 to YTD 2013 31




...